RPS19 and beta thalassemia: The successful development of gene therapy for RPS19-deficient DBA opens the possibilities for other mutations of DBA, such as RPL5 and RPL11. In addition, gene therapy using CRISPR-Cas9 genome editing tools also showed therapeutic effects for genetic blood disorders such as sickle cell disease and beta-thalassemia [117–119].